

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Gaush Meditech Ltd

高視医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2407)

VOLUNTARY ANNOUNCEMENT INTRAOCULAR LENS IMPLANT SYSTEM OBTAINED MEDICAL DEVICE REGISTRATION CERTIFICATE IN CHINA

This announcement is made by Gaush Meditech Ltd (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis, to inform the shareholders and potential investors of the Company regarding the latest business development of the Group.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce that Gaush Teleon Ltd* (高視泰靚醫療科技有限公司) (“**Gaush Teleon**”), a wholly-owned subsidiary of the Company, has recently obtained the medical device registration certificate for its “intraocular lens implant system” from the Guangdong Provincial Medical Products Administration.

Chinese Guideline for Cataract Surgery in Adults (2023) indicates that cataract is the leading cause of blindness worldwide. In the backdrop of growing aging population, the incidence rate of cataract increases year by year. As of 2020, incidence rate of cataract among Chinese adults (aged 18 and higher) reached 22.78%. Total number of patients reached 130,000,000. It is expected that by 2050, China will have more than 240,000,000 adults suffering from cataract. Currently, general cataract surgeries include extracapsular cataract extraction, manual small-incision cataract surgery, phacoemulsification and femtosecond laser-assisted cataract surgery. These surgeries require the application of intraocular lens implant system to infuse the eyes with intraocular lens to replace the unclear natural crystalline lens, thus recovering the eyesight of such patients.

The intraocular lens implant system (Registration Certificate No.: Yue Xie Zhu Zhun 20252160605) of Gaush Teleon approved this time is mainly applicable for intraocular lens implantation during manual small-incision cataract surgery. Compared to the intraocular lens implant system (Registration Certificate No.: Yue Xie Zhu Zhun 20242161490) approved in 2024, it reduces the surgical incision to below 1.8mm, which minimizes corneal trauma and accelerates post-surgical recovery, while also achieves ultra-low resistance lens implantation and significant increase of surgery efficiency with the chemically-grafted lubrication coating on the spatula.

This product is an original design of Gaush Teleon and has obtained an invention patent. The technical features of this invention patent are that spatulas of different models and specifications could be installed on the main trocar for use in intraocular lens implantation with different surgical incision sizes. Meanwhile, it can also be expanded into a pre-installed implantation system, which accommodates intraocular lens implantation with any intraocular lens on the market.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board

Gaush Meditech Ltd

Mr. Gao Tieta

Chairman and Executive Director

Hong Kong, May 9, 2025

As of the date of this announcement, the Board comprises Mr. Gao Tieta as Chairman and executive Director, Mr. Liu Xinwei, Mr. Zhao Xinli, Mr. Zhang Jianjun and Ms. Li Wenqi as executive Directors, Dr. David Guowei Wang as non-executive Director, and Mr. Feng Xin, Mr. Wang Li-Shin and Mr. Chan Fan Shing as independent non-executive Directors.

* *For identification purpose only*